EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

Shaun G Goodman iD, Philippe Gabriel Steg, Michael Szarek iD, Deepak L Bhatt iD, Vera A Bittner, Rafael Diaz iD, Robert A Harrington, J Wouter Jukema iD, Harvey D White, Andreas M Zeiher, Garen Manvelian, Robert Pordy iD und 5 weitere

European Heart Journal - Cardiovascular Pharmacotherapy · 2024

DOI: 10.1093/ehjcvp/pvae025 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, 2024. Verfasst von Shaun G Goodman und 16 weiteren Autor:innen. Beteiligte Einrichtung: Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Cholesterol, LDL, PCSK9 Inhibitors. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi, Regeneron Pharmaceuticals, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ODYSSEY OUTCOMES trial, comprising over 47 000 patient-years of placebo-controlled observation, demonstrated important reductions in the risk of recurrent ischaemic cardiovascular events with the monoclonal antibody to proprotein convertase subtilisin/kexin type 9 alirocumab, as well as lower all-cause death. These benefits were observed in the context of substantial and persistent lowering of low-density lipoprotein cholesterol with alirocumab compared with that achieved with placebo. The safety profile of alirocumab was indistinguishable from matching placebo except for a ∼1.7% absolute increase in local injection site reactions. Further, the safety of alirocumab compared with placebo was evident in vulnerable groups identified before randomization, such as the elderly and those with diabetes mellitus, previous ischaemic stroke, or chronic kidney disease. The frequency of adverse events and laboratory-based abnormalities was generally similar to that in placebo-treated patients. Thus, alirocumab appears to be a safe and effective lipid-modifying treatment over a duration of at least 5 years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCholesterol, LDLPCSK9 InhibitorsHumansAnticholesteremic AgentsBiomarkersCardiovascular DiseasesDyslipidemiasProprotein Convertase 9Randomized Controlled Trials as TopicSerine Proteinase InhibitorsTime FactorsTreatment Outcome

Stichwörter der Autor:innen

AlirocumabCholesterolPCSK9Safety

Substanzen

alirocumabAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsBiomarkersCholesterol, LDLPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9Serine Proteinase Inhibitors

Autor:innen und Institutionen

  • Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada.
  • St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
  • Université Paris-Cité, Institut Universitaire de France, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, FACT (French Alliance for Cardiovascular Trials), and INSERM U1148, F-75018 Paris, France.
  • CPC Clinical Research and Division of Cardiology, University of Colorado School of Medicine, Aurora, 80045 CO, USA.
  • State University of New York, Downstate Health Sciences University, Brooklyn, NY 11203, USA.
  • Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

ORCID-Profile: Shaun G Goodman, Michael Szarek, Deepak L Bhatt, Rafael Diaz, J Wouter Jukema, Robert Pordy

Förderung

  • Sanofi
  • Regeneron Pharmaceuticals, Inc.

Zitieren

APA

Goodman, S. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Harrington, R. A., Jukema, J. W., White, H. D., Zeiher, A. M., Manvelian, G., Pordy, R., Poulouin, Y., Stipek, W., Garon, G., Schwartz, G. G., & ODYSSEY OUTCOMES Investigators (2024). Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvae025

Vancouver

Goodman SG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation. European Heart Journal - Cardiovascular Pharmacotherapy. 2024. doi:10.1093/ehjcvp/pvae025

BibTeX
@article{Goodman2024,
  author = {Goodman, Shaun G and Steg, Philippe Gabriel and Szarek, Michael and Bhatt, Deepak L and Bittner, Vera A and Diaz, Rafael and Harrington, Robert A and Jukema, J Wouter and White, Harvey D and Zeiher, Andreas M and Manvelian, Garen and Pordy, Robert and Poulouin, Yann and Stipek, Wanda and Garon, Genevieve and Schwartz, Gregory G and ODYSSEY OUTCOMES Investigators, ODYSSEY OUTCOMES Investigators},
  title = {Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation},
  journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
  year = {2024},
  doi = {10.1093/ehjcvp/pvae025}
}
Kostenlos starten →